Literature DB >> 31653644

Toward Combined Cell and Gene Therapy for Genodermatoses.

Laura De Rosa1, Maria Carmela Latella1, Alessia Secone Seconetti1, Cecilia Cattelani2, Johann W Bauer3, Sergio Bondanza1, Michele De Luca2.   

Abstract

To date, more than 200 monogenic, often devastating, skin diseases have been described. Because of unmet medical needs, development of long-lasting and curative therapies has been consistently attempted, with the aim of correcting the underlying molecular defect. In this review, we will specifically address the few combined cell and gene therapy strategies that made it to the clinics. Based on these studies, what can be envisioned for the future is a patient-oriented strategy, built on the specific features of the individual in need. Most likely, a combination of different strategies, approaches, and advanced therapies will be required to reach the finish line at the end of the long and winding road hampering the achievement of definitive treatments for genodermatoses.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 31653644      PMCID: PMC7197428          DOI: 10.1101/cshperspect.a035667

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  196 in total

1.  Regeneration of a bioengineered 3D integumentary organ system from iPS cells.

Authors:  Koh-Ei Toyoshima; Miho Ogawa; Takashi Tsuji
Journal:  Nat Protoc       Date:  2019-04-08       Impact factor: 13.491

2.  Quality of life in epidermolysis bullosa.

Authors:  H M Horn; M J Tidman
Journal:  Clin Exp Dermatol       Date:  2002-11       Impact factor: 3.470

Review 3.  CRISPR/Cas9 for genome editing: progress, implications and challenges.

Authors:  Feng Zhang; Yan Wen; Xiong Guo
Journal:  Hum Mol Genet       Date:  2014-03-20       Impact factor: 6.150

Review 4.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.

Authors:  Michael R Lieber
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 5.  Non-herlitz junctional epidermolysis bullosa.

Authors:  Kim B Yancey; Helmut Hintner
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

6.  Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.

Authors:  Kerstin B Kaufmann; Christian Brendel; Julia D Suerth; Uta Mueller-Kuller; Linping Chen-Wichmann; Joachim Schwäble; Shweta Pahujani; Hana Kunkel; Axel Schambach; Christopher Baum; Manuel Grez
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

7.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.

Authors:  Suk See De Ravin; Xiaolin Wu; Susan Moir; Sandra Anaya-O'Brien; Nana Kwatemaa; Patricia Littel; Narda Theobald; Uimook Choi; Ling Su; Martha Marquesen; Dianne Hilligoss; Janet Lee; Clarissa M Buckner; Kol A Zarember; Geraldine O'Connor; Daniel McVicar; Douglas Kuhns; Robert E Throm; Sheng Zhou; Luigi D Notarangelo; I Celine Hanson; Mort J Cowan; Elizabeth Kang; Coleen Hadigan; Michael Meagher; John T Gray; Brian P Sorrentino; Harry L Malech
Journal:  Sci Transl Med       Date:  2016-04-20       Impact factor: 17.956

8.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 9.  Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union.

Authors:  Graziella Pellegrini; Diego Ardigò; Giovanni Milazzo; Giorgio Iotti; Paolo Guatelli; Danilo Pelosi; Michele De Luca
Journal:  Stem Cells Transl Med       Date:  2017-12-27       Impact factor: 6.940

10.  Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.

Authors:  Araksya Izmiryan; Clarisse Ganier; Matteo Bovolenta; Alain Schmitt; Fulvio Mavilio; Alain Hovnanian
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-26       Impact factor: 8.886

View more
  8 in total

Review 1.  Tracing the Dynamics of Stem Cell Fate.

Authors:  Lemonia Chatzeli; Benjamin D Simons
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-06-01       Impact factor: 9.708

2.  Single-keratinocyte transcriptomic analyses identify different clonal types and proliferative potential mediated by FOXM1 in human epidermal stem cells.

Authors:  Elena Enzo; Alessia Secone Seconetti; Mattia Forcato; Elena Tenedini; Maria Pia Polito; Irene Sala; Sonia Carulli; Roberta Contin; Clelia Peano; Enrico Tagliafico; Silvio Bicciato; Sergio Bondanza; Michele De Luca
Journal:  Nat Commun       Date:  2021-05-04       Impact factor: 14.919

Review 3.  The Potential of CRISPR-Guided Therapies in the Dermatology Clinic.

Authors:  Prashant Bhat; Lilit Garibyan
Journal:  JID Innov       Date:  2022-01-25

4.  Profiling trial burden and patients' attitudes to improve clinical research in epidermolysis bullosa.

Authors:  Christine Prodinger; Anja Diem; Katherina Ude-Schoder; Josefina Piñón-Hofbauer; Sophie Kitzmueller; Johann W Bauer; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-07-10       Impact factor: 4.123

Review 5.  Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery.

Authors:  Vignesh Jayarajan; Evangelia Kounatidou; Waseem Qasim; Wei-Li Di
Journal:  Exp Dermatol       Date:  2021-03-11       Impact factor: 3.960

6.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

Review 7.  Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa.

Authors:  Tobias Welponer; Christine Prodinger; Josefina Pinon-Hofbauer; Arno Hintersteininger; Hannelore Breitenbach-Koller; Johann W Bauer; Martin Laimer
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-10

8.  Self-assembly of differentiated progenitor cells facilitates spheroid human skin organoid formation and planar skin regeneration.

Authors:  Patricia Ebner-Peking; Linda Krisch; Martin Wolf; Sarah Hochmann; Anna Hoog; Balázs Vári; Katharina Muigg; Rodolphe Poupardin; Cornelia Scharler; Sabine Schmidhuber; Elisabeth Russe; Harald Stachelscheid; Achim Schneeberger; Katharina Schallmoser; Dirk Strunk
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.